Major Study Reveals Cardiovascular Risks of Stopping GLP-1 Treatment
A groundbreaking study published March 18, 2026 in BMJ Medicine has revealed alarming findings about what happens when patients discontinue GLP-1 medications. Researchers at Washington University School of Medicine found that stopping GLP-1 drugs such as semaglutide and tirzepatide — even temporarily — elevates the risk of heart attack, stroke and death compared to staying on the medication continuously. The study followed more than 333,000 U.S. veterans with type 2 diabetes for three years.
The findings represent some of the most comprehensive real-world evidence to date on the cardiovascular consequences of GLP-1 discontinuation, with significant implications for the millions of Americans currently using these medications.
Rapid Loss of Heart Protection
Compared with those who remained on the drug, people who discontinued GLP-1 medication had a 4% increase in heart risks six months after going off the drug, a 14% increase in risk at a year off the medication, and a 22% increase in risk by the second year off the medication, which meant the benefits they'd seen had virtually been erased by that point.
The study's lead author, Dr. Ziyad Al-Aly, described the phenomenon as "metabolic whiplash" where "when they stop, it's not just weight that comes back; they experience a resurgence in inflammation, blood pressure, and cholesterol. Weight regain is visible; the metabolic reversal is not."
Three Years of Benefits Lost in Half the Time
"It takes a whole lot longer to build or accrue benefit, and then half as much to erase all that benefit," Al-Aly explained. "For example, what took three years to build — three years of the cardiovascular benefit — was actually erased or undone with just one and a half years of stopping."
Participants who consistently took GLP-1 medications for the entire three-year period of the study had the most pronounced reduction in risk—18%, or roughly four fewer major cardiovascular events per 100 people over three years. However, those benefits were progressively lost as treatment gaps increased.
High Discontinuation Rates Highlight Treatment Challenges
Studies show roughly half of people who start taking GLP-1 drugs will stop within one year. The major reasons for that are side effects like nausea and fatigue and cost – about half the people who stop say they can't afford to stay on them.
According to Al-Aly, an estimated 1 in 8 adults in the U.S. has used a GLP-1, with 36 to 81 percent ditching the drugs within the first year, either due to meeting their weight-loss goals, high cost, or concern over side effects.
Implications for Patients and Providers
The research underscores the importance of viewing GLP-1 treatment as a long-term commitment rather than a temporary intervention. "The implications are clear: clinicians should treat persistence as a clinical outcome in its own right," Al-Aly said. "Health systems need to identify and support patients at risk of stopping. And policymakers need to address the barriers, financial and otherwise, that make continuous treatment unsustainable for many. The data show a clear dose-response: the more consistently people stay on, the greater the heart protection."
Sources
- BMJ Medicine Study - Washington University research on GLP-1 discontinuation cardiovascular risks
- CNN Health Coverage - Analysis of heart benefit findings
- Military.com Report - VA study details and implications
- U.S. News Coverage - Additional study analysis and expert commentary